 | Up a level |
Munzone, E.; Giobbie-Hurder, A.; Gusterson, B. A.; Mallon, E.; Viale, G.; Thürlimann, B.; Ejlertsen, B.; Macgrogan, G.; Bibeau, F.; Lelkaitis, G.; Price, K. N.; Gelber, R. D.; Coates, A. S.; Goldhirsch, A.; Colleoni, M. (2015). Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of oncology, 26(12), pp. 2442-2449. Oxford University Press 10.1093/annonc/mdv391
Huober, J.; Cole, B. F.; Rabaglio, Manuela; Giobbie-Hurder, A.; Wu, J.; Ejlertsen, B.; Bonnefoi, H.; Forbes, J. F.; Neven, P.; Láng, I.; Smith, I.; Wardley, A.; Price, K. N.; Goldhirsch, A.; Coates, A. S.; Colleoni, M.; Gelber, R. D.; Thürlimann, B. (2014). Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast cancer research and treatment, 143(1), pp. 159-169. Springer 10.1007/s10549-013-2792-7
Curigliano, G.; Cardinale, D.; Suter, T.; Plataniotis, G.; De Azambuja, E.; Sandri, M. T.; Criscitiello, C.; Goldhirsch, A.; Cipolla, C.; Roila, F. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of oncology, 23(suppl 7), vii155-vii166. Oxford University Press 10.1093/annonc/mds293
Viale, G.; Giobbie-Hurder, A.; Gusterson, B. A.; Maiorano, E.; Mastropasqua, M. G.; Sonzogni, A.; Mallon, E.; Colleoni, M.; Castiglione-Gertsch, M.; Regan, M. M.; Price, K. N.; Brown, R. W.; Golouh, R.; Crivellari, D.; Karlsson, P.; Öhlschlegel, C.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S. (2009). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology, 21(2), pp. 245-254. Oxford University Press 10.1093/annonc/mdp317
Ravaioli, A.; Monti, F.; Regan, M. M.; Maffini, F.; Mastropasqua, M. G.; Spataro, V.; Castiglione-Gertsch, Monica; Panzini, I.; Gianni, L.; Goldhirsch, A.; Coates, A.; Price, K. N.; Gusterson, B. A.; Viale, G. (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of oncology, 19(4), pp. 660-668. Oxford University Press 10.1093/annonc/mdm547
Regan, M. M.; Pagani, O.; Walley, B.; Torrisi, R.; Perez, E. A.; Francis, P.; Fleming, G. F.; Price, K. N.; Thürlimann, B.; Maibach, R.; Castiglione-Gertsch, M.; Coates, A. S.; Goldhirsch, A.; Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of oncology, 19(7), pp. 1231-1241. Oxford University Press 10.1093/annonc/mdn037
Roth, A. D.; Maibach, R.; Fazio, N.; Sessa, C.; Stupp, R.; Morant, R.; Herrmann, R.; Borner, M. M.; Goldhirsch, A.; De Braud, F. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of oncology, 15(5), pp. 759-764. Oxford University Press 10.1093/annonc/mdh187
Waeber, M.; Castiglione-Gertsch, M.; Dietrich, D.; Thürlimann, B.; Goldhirsch, A.; Brunner, K. W.; Borner, M. M. (2003). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology, 14(8), pp. 1215-1221. Oxford University Press 10.1093/annonc/mdg347
Crivellari, D.; Pagani, O.; Veronesi, A.; Lombardi, D.; Nolè, F.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Sessa, C.; Goldhirsch, A. (2001). High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology, 12(3), pp. 353-356. Oxford University Press 10.1023/A:1011132609055
Pagani, O.; Sessa, C.; Nolè, F.; Crivellari, D.; Lombardi, D.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Zucchetti, M.; D'Incalci, M.; Goldhirsch, A. (2000). Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study. Annals of oncology, 11(8), pp. 985-991. Oxford University Press 10.1023/A:1008392927656
Roth, A. D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M. S.; Pagani, O.; Morant, R.; Borner, M. M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch, A. (2000). Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. Annals of oncology, 11(3), pp. 301-306. Oxford University Press 10.1023/A:1008342013224
Pagani, O.; Sessa, C.; Martinelli, G.; Crivellari, D.; Buonadonna, A.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Zampino, G.; Zimatore, M.; Graffeo, R.; Riva, A.; Goldhirsch, A. (1999). Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology, 10(5), pp. 539-545. Oxford University Press 10.1023/A:1026437731354
Goldhirsch, A.; Coates, A. S.; Castiglione-Gertsch, M.; Gelber, R. D. (1998). New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction? Annals of oncology, 9(9), pp. 973-976. Oxford University Press 10.1023/A:1008436810268
Borner, M. M.; Castiglione, M.; Bacchi, M.; Weber, Walter; Herrmann, R.; Fey, M. F.; Pagani, O.; Leyvraz, S.; Morant, R.; Pestalozzi, B.; Hanselmann, S.; Goldhirsch, A. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of oncology, 9(5), pp. 535-541. Oxford University Press 10.1023/A:1008270916325
Pagani, O.; Sessa, C.; Martinelli, G.; Cerny, Thomas; De Jong, J.; Goldhirsch, A.; Zimatore, M.; Cavalli, F. (1997). Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Annals of oncology, 8(7), pp. 655-661. Oxford University Press 10.1023/A:1008211629858
Goldhirsch, A.; Gelber, R. D.; Castiglione, M.; O'Neill, A.; Thürlimann, B.; Rudenstam, C.-M; Lindtner, J.; Collins, J.; Forbes, J.; Crivellari, D.; Coates, A.; Cavalli, F.; Simoncini, E.; Fey, M. F.; Pagani, O.; Price, K.; Senn, H.-J. (1997). Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of oncology, 8(8), pp. 751-756. Oxford University Press 10.1023/A:1008220301866
Buser, K.; Bacchi, M.; Goldhirsch, A.; Greiner, R.; Diener, P.; Sessa, C.; Jungi, W. F.; Forni, M.; Leyvraz, S.; Engeler, V. (1996). Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Annals of oncology, 7(1), pp. 65-70. Oxford University Press 10.1093/oxfordjournals.annonc.a010481
Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635
